Stage IVB Cervical Cancer
Current Clinical Trials
No standard chemotherapy treatment is available for patients with stage IVB cervical
cancer that provides substantial palliation. These patients are appropriate
candidates for clinical trials testing single agents or combination
chemotherapy employing agents listed below or new anticancer treatments in
phase I and II clinical trials.[1]
Treatment options:
- Radiation therapy may be used to palliate central disease or distant
metastases.
- Chemotherapy. Tested drugs include:
- Cisplatin (15%–25% response rate).[1,2]
- Ifosfamide (31% response rate). [3]
- Paclitaxel (17% response rate).[4-6]
- Ifosfamide-cisplatin.[7,8]
- Irinotecan (21% response rate in patients previously treated with
chemotherapy).[9]
- Paclitaxel/cisplatin (46% response rate).[10]
- Cisplatin/gemcitabine (41% response rate).[11]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage IVB cervical cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Alberts DS, Kronmal R, Baker LH, et al.: Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. J Clin Oncol 5 (11): 1791-5, 1987.
[PUBMED Abstract]
-
Thigpen JT, Blessing JA, DiSaia PJ, et al.: A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 32 (2): 198-202, 1989.
[PUBMED Abstract]
-
Coleman RE, Harper PG, Gallagher C, et al.: A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 18 (3): 280-3, 1986.
[PUBMED Abstract]
-
Kudelka AP, Winn R, Edwards CL, et al.: Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res 2 (8): 1285-8, 1996.
[PUBMED Abstract]
-
Thigpen T, Vance RB, Khansur T: The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 22 (5 Suppl 12): 67-75, 1995.
[PUBMED Abstract]
-
McGuire WP, Blessing JA, Moore D, et al.: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14 (3): 792-5, 1996.
[PUBMED Abstract]
-
Buxton EJ, Meanwell CA, Hilton C, et al.: Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81 (5): 359-61, 1989.
[PUBMED Abstract]
-
Omura GA, Blessing JA, Vaccarello L, et al.: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15 (1): 165-71, 1997.
[PUBMED Abstract]
-
Verschraegen CF, Levy T, Kudelka AP, et al.: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15 (2): 625-31, 1997.
[PUBMED Abstract]
-
Rose PG, Blessing JA, Gershenson DM, et al.: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17 (9): 2676-80, 1999.
[PUBMED Abstract]
-
Burnett AF, Roman LD, Garcia AA, et al.: A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 76 (1): 63-6, 2000.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |